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Histone mRNA levels are cell cycle regulated, and a major regulatory mechanism is restriction of stem-loop
binding protein (SLBP) to S phase. Degradation of SLBP at the end of S phase results in cessation of histone
mRNA biosynthesis, preventing accumulation of histone mRNA until SLBP is synthesized just before entry into
the next S phase. Degradation of SLBP requires an SFTTP (58 to 62) and KRKL (95 to 98) sequence, which
is a putative cyclin binding site. A fusion protein with the 58-amino-acid sequence of SLBP (amino acids 51 to
108) fused to glutathione S-transferase (GST) is sufficient to mimic SLBP degradation at late S phase. Using
GST-SLBP fusion proteins as a substrate, we show that cyclin A/Cdk1 phosphorylates Thr61. Furthermore,
knockdown of Cdk1 by RNA interference stabilizes SLBP at the end of S phase. Phosphorylation of Thr61 is
necessary for subsequent phosphorylation of Thr60 by CK2 in vitro. Inhibitors of CK2 also prevent degrada-
tion of SLBP at the end of S phase. Thus, phosphorylation of Thr61 by cyclin A/Cdk1 primes phosphorylation
of Thr60 by CK2 and is responsible for initiating SLBP degradation. We conclude that the increase in cyclin
A/Cdk1 activity at the end of S phase triggers degradation of SLBP at S/G2.
Progression through the cell cycle is driven by a class of
protein kinases, the cyclin-dependent kinases (cdk’s), which
are sequentially activated as cells progress from one cell cycle
stage to the next. In particular, progress into S phase requires
the activation of cyclin E/Cdk2, ultimately resulting in the
initiation of DNA replication, and progression through mitosis
requires the activation of cyclin B/Cdk1 (cdc2), resulting in
nuclear envelope breakdown and chromosome condensation
(27). Cyclin A/Cdk2 activity is required for continued progres-
sion through S phase (36). The targets of the cdk’s are acti-
vated or inactivated by phosphorylation. A second critical reg-
ulatory mechanism for cell cycle progression is targeted
proteolysis of key protein regulators (13). These include the
cyclin subunits of the cdk’s, critical proteins in initiation of
DNA replication, and proteins responsible for maintaining
chromosome pairing (6).
While much is known about the events that must occur for
cells to transit from G1 to S phase and for cells to enter and
exit mitosis, much less is known about the molecular events
at the end of S phase, as cells progress from S to G2 phase.
S phase is characterized by replication of the chromosomes,
and at the same time DNA is replicated, histone proteins
must be synthesized to provide histones to assemble the
newly replicated chromatin. Histone mRNAs are cell cycle
regulated, and their expression is restricted to S phase. The
metazoan replication-dependent histone mRNAs are the
only eukaryotic cellular mRNAs that are not polyadenyl-
ated. Instead, they end in a conserved stem-loop sequence
(18). Since the replication-dependent histone genes lack
introns, the only processing reaction required for histone
mRNA biosynthesis is cleavage of the nascent transcript to
form the 3 end of the mRNA (18).
The 3 end of histone mRNAs is a major cis element re-
sponsible for the coordinated regulation of histone mRNA
levels (17). The 3 end is bound by the stem-loop binding
protein (SLBP), which is required for both histone pre-mRNA
processing and histone mRNA translation (18). The processing
of histone pre-mRNA is cell cycle regulated, as is the stability
of histone mRNAs (11). SLBP is also a cell cycle-regulated
protein, accumulating only in S-phase cells (34), and regulation
of SLBP levels is an important component of the cell cycle
regulation of histone mRNA. SLBP is rapidly degraded at the
end of S phase as a result of phosphorylation of two threonines
in an SFTTP sequence (amino acids 58 to 62). Proline 62 is
also required for SLBP degradation (37), as is a KRKL se-
quence (amino acids 95 to 98) that is a consensus cyclin binding
site (1–3, 5, 30) thought to primarily interact with the S-phase
cyclins A and E (16).
We report here that cyclin A/Cdk1 initiates SLBP degrada-
tion at the end of S phase by phosphorylating Thr61. Subse-
quent to that phosphorylation, CK2 phosphorylates T60, and
the doubly phosphorylated SLBP is targeted for degradation.
Cyclin A/Cdk1 activity is cell cycle regulated and is the major
activity in late-S-phase cells that phosphorylates Thr61 of
SLBP. We propose that cyclin A/Cdk1 is activated near the end
of S phase, resulting in the degradation of SLBP and down-
regulating histone mRNA synthesis. It is likely that cyclin
A/Cdk1 phosphorylates other targets at the same time, during
the transition from S phase to G2 phase.
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MATERIALS AND METHODS
Construct preparation. For bacterial expression, the SBLP fragment (51 to
108) was subcloned into the PGEX2T vector just after the glutathione S-trans-
ferase (GST) tag using a PCR-generated insert with EcoRI and BamHI sites. For
expression in HeLa cells, the GST-fused SLBP fragment was subcloned into a
Myc-tagged pcDNA3 vector (Invitrogen) by PCR-generated insertion with XhoI
and KpnI sites. All site-directed mutations were made according to the Quick-
Change site-directed mutagenesis protocols (Stratagene) using appropriate com-
plementary oligonucleotides ranging from 30 to 50 nucleotides in length. All
constructs were verified by DNA sequencing.
Transfection and selection of stable cell lines. HeLa cell plasmid transfections
were done with Lipofectamine (GibcoBRL) according to the manufacturer’s
protocol. Two micrograms of each plasmid was used with each six-well plate. For
selection of stably transfected cells, the cells were replated onto a fresh 10-cm
plate 24 h after transfection with medium containing 1 mg/ml G418. The medium
containing G418 was changed every 5 days to remove dead cells. Cells were kept
under selection until separate colonies could be observed by eye on the plates,
and these stably transfected cells (at least 20 colonies per plate) were pooled
together. To maintain the stably transfected cells, 200 g of G418 per ml was
kept in the medium and was removed just prior to synchronization.
Cell culture and synchronization. HeLa cells were grown in Dulbecco modi-
fied Eagle medium plus 10% fetal bovine serum and penicillin-streptomycin.
Cells were synchronized at the G1/S border by a double-thymidine block. Cells
were plated at a low density 24 h before the start of the synchronization protocol,
when cells were treated with 2 mM thymidine for 18 h for the initial block. After
the initial block, cells were washed with phosphate-buffered saline, released into
fresh medium for 9 h, and then blocked again with 2 mM thymidine for 16 h to
arrest all the cells at the beginning of S phase. The cells were released into fresh
medium after the thymidine was washed out, and lysates were prepared from the
cells collected at various time points after the release. The cells progressed
through G2 and mitosis synchronously. The cell cycle profile of the cells was
determined by propidium iodide staining and flow cytometry analysis at the
University of North Carolina (UNC) Flow Cytometry facility.
Lysate preparation and in vitro kinase assays. Cells were collected at the
indicated time points after release from a double-thymidine block, resuspended
in lysis buffer (50 mM -glycerophosphate, 20 mM NaF, 1.5 mM EGTA, 0.05%
NP-40 with 1 mM dithiothreitol, 1 mM phenylmethylsulfonyl fluoride, and 500
M Na3VO4), and sonicated four times on ice (800 l per 10-cm dish). Extracts
were clarified by centrifugation for 10 min at 14,000 rpm at 4°C. In vitro kinase
assays were performed in a 30 l reaction mix (supplemented with a final 10 mM
concentration of MgCl2 and 5 M concentration of ATP) with the corresponding
lysate (1 to 2 mg/ml protein; 10 g protein) and 1 g of substrate (GST-SLBP
fragment or H1) in lysis buffer and 8 Ci of [-32P]ATP. In each reaction,
immunoprecipitates on beads (from 80 to 100 g lysate), the supernatant from
the immunoprecipitates, or the lysate directly was used as a kinase source as
indicated. The reactions were incubated at 30°C for 30 min and stopped by
adding 2 sodium dodecyl sulfate (SDS) loading buffer. Samples were analyzed
by SDS-polyacrylamide gel electrophoresis (PAGE) and each gel stained with
Coomassie, dried, analyzed by autoradiography, and quantified with a
PhosphorImager.
Recombinant kinases. Baculovirus-expressed recombinant cyclin A/Cdk2, cy-
clin B/Cdk1, and cyclin A/Cdk1 were obtained from Cell Signaling. Bacterially
expressed recombinant casein kinase 2 (CK2) (alpha and beta subunits) was
purchased from New England Biolabs. With cdk’s and sequential phosphoryla-
tion experiments, kinase reactions were carried out in the kinase buffer described
above. For phosphorylation with CK2 alone, the commercial buffer provided by
NEB was used.
Analysis of phosphorylation sites. Synthetic peptides corresponding to resi-
dues 54 to 68 of SLBP (54RRPESFTTPEGPKPR68), with the T at position 61
unmodified or phosphorylated and the same peptide with a phosphothreonine at
Thr61[TphosTP], were synthesized. These were incubated with casein kinase II
in the presence of [-32P]ATP and the amount of phosphorylation determined by
binding to DEAE-cellulose followed by scintillation counting. The phosphoryla-
tion reaction was also carried out with unlabeled ATP and the peptides analyzed
by mass spectrometry (matrix-assisted laser desorption ionization [MALDI])
using an ABI4800 TOF/TOF mass spectrometer.
Following phosphorylation of the recombinant GST-SLBP proteins with re-
combinant cyclin A/Cdc2 and/or CK2, the proteins were analyzed by mass spec-
trometry using electrospray as previously described (8). The sites of phosphory-
lation were confirmed by digesting GST-SLBP with trypsin and analyzing the
peptides on an ABI4800 TOF/TOF mass spectrometer.
RNA interference. Downregulation of Cdk1 expression was obtained by trans-
fection of chemically synthesized small interfering RNA (siRNA) using oligo-
fectamine 2000 transfection according to the manufacturer’s protocol. Chemi-
cally synthesized siRNAs were obtained from Dharmacon (Lafayette, CO) and
had the following sequences of the top strand: 5AAGGGGUUCCUAGUACU
GCAAdTdT3 and 5GGUCCGGCUCCCCCAAAUGdTdT3 (control, C2). A
portion of cells were lysed in a buffer containing 150 mM NaCl, 50 mM Tris-HCl
(pH 8), 1 mM dithiothreitol, 1 mM phenylmethylsulfonyl fluoride, 1 protease
inhibitor mixture (Roche), and 0.5% NP-40 and analyzed by Western blotting.
The remaining cells were fixed with 70% ethanol, stained with propidium iodide,
and analyzed for their DNA content by flow cytometry with a FACscan instru-
ment and the Summit software (Cytomation, Inc.).
Antibodies and inhibitors. SLBP was detected with an antibody raised against
the C-terminal 13 amino acids of the protein (32). Cyclin A and cyclin B anti-
bodies used in Western blots and immunoprecipitation experiments were pur-
chased from Neomarkers (Feremont, CA) and SantaCruz (Santa Cruz, CA),
respectively. Cdk1 and Cdk2 antibodies were a kind gift from Yue Xiong (UNC).
All the kinase inhibitors tested were purchased from Calbiochem (La Jolla, CA).
RESULTS
A cyclin/cdk is required for degradation of SLBP at S/G2
transition. SLBP expression is limited to S phase (34), and at
the end of S phase, SLBP is rapidly degraded (37) (Fig. 1A).
Previously we have shown that SLBP degradation requires
phosphorylation of two threonine residues (Thr60 and Thr61)
by two different kinases (37). Further, we have shown that
along with Thr60 and Thr61, Pro62 and a downstream KRKL
sequence are required for SLBP degradation at the end of S
phase (37). The observation that Thr61 is a possible cdk phos-
phorylation site and KRKL is a putative cyclin binding site
suggested that a cyclin/cdk was involved in SLBP degradation
by phosphorylating Thr61. To test this possibility, we examined
the affects of roscovitine, a known Cdk1/Cdk2 inhibitor, on
FIG. 1. S/G2 degradation of SLBP is roscovitine sensitive.
(A) Western blot analysis of SLBP levels in HeLa cells synchronized by
a double-thymidime block and collected at the indicated time points
after the release. (B) FACS analysis of the cells collected at indicated
times after the release. (C) Western blot analysis of SLBP levels in
HeLa cells which were treated with either dimethyl sulfoxide (DMSO,
lane 2) or 20 M roscovitine (Ros, lane 3) in DMSO 4 h after release
from the double-thymidine block and collected four more hours later.
(D) FACS analysis of both Ros- and DMSO-treated cells at the time
of collection.
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SLBP degradation at S/G2 in HeLa cells. At the end of S phase,
the level of SLBP remained higher in cells treated with rosco-
vitine than in dimethylsulfoxide (DMSO)-treated control cells
(Fig. 1C). Fluorescence-activated cell sorting (FACS) analysis
confirmed that both cell populations successfully completed S
phase and accumulated at G2 without a significant difference in
their cell cycle profile at the time of collection (Fig. 1D). Since
roscovitine is specific to Cdk1/Cdk2 (7, 20), we hypothesized
that one or both of these cdk’s was involved in SLBP degra-
dation, possibly by phosphorylating Thr61. Several other ki-
nase inhibitors were tested by adding them to cells in mid-S
phase. However, none of these inhibitors, including other in-
hibitors of proline-dependent kinases, inhibited the degrada-
tion of SLBP at the end of S phase (Table 1).
In order to determine whether phosphorylation of these two
residues and the presence of the KRKL sequence were suffi-
cient to trigger SLBP degradation, we designed a Myc-tagged
GST protein fused to amino acids 51 to 108 of an SLBP
fragment (mGST-SLBPF) in which all of the serines and
threonines except Thr60 and Thr61 were mutated to alanine.
We constructed similar genes encoding mutation of Thr60,
Thr61, and the KRKL sequence to alanine. We stably ex-
pressed the wild type and Thr61A mGST-SLBPF in HeLa cells
and then synchronized the cells by a double-thymidine block.
Chimeric wild-type mGST-SLBPF was degraded at G2 in par-
allel with endogenous SLBP (Fig. 2B, lane 1 and lane 2).
mGST-SLBPF with the Thr61A mutation was stable during G2
phase (Fig. 2B, lanes 3 and 4). This result confirmed that
mGST-SLBPF was degraded by a mechanism similar to that
with full-length SLBP, since mutation of Thr61 to alanine in
full-length SLBP also prevented SLBP degradation at the end
of S phase (37).
We next expressed the GST-SLBP fragment (51 to 108
amino acids) in bacteria and used the recombinant GST-
SLBPF protein as a substrate for in vitro kinase assays. We also
constructed and expressed similar GST fusion proteins con-
taining TAP or ATP in place of the TTP (amino acids 60 to 62)
sequence or a mutant with the KRKL sequence changed to
four alanines (KRKL/4A). We prepared an extract from late-
S-phase cells (6 h after release from a double-thymidine block)
and tested this extract as a source of kinase activity. The extract
phosphorylated the wild-type GST-SLBPF and the ATP mu-
tant (Fig. 2C, lanes 1 and 2) but not the TAP mutant or GST
protein (Fig. 2C, lanes 3 and 6). The activity was sensitive to
roscovitine, demonstrating that this phosphorylation was me-
diated by Cdk1 or Cdk2 (Fig. 2C, lanes 4 and 5). Moreover,
these results suggested that Thr61 was the only site in the
GST-SLBP fragment phosphorylated by the kinase(s) in this
lysate.
Phosphorylation of Thr61 increases in lysates from late-S,
G2-phase cells. To determine whether the kinase activity re-
sponsible for the Thr61 phosphorylation was regulated during
the cell cycle, we performed in vitro kinase assays using the
GST-SLBPF protein as a substrate and lysates from HeLa cells
isolated at different time points in the cell cycle as the kinase
source. We tested extracts prepared from cells at different
times after release from the thymidine block. The lysates pre-
pared from G1/S (0 h), mid-S phase (4 h), S/G2 (6 h), M/G1 (10
or 11 h), and early and mid-G1 (12 and 14 h) were tested with
the wild-type GST-SLBPF substrate, and we detected peak
phosphorylation at late S phase (S/G2) overlapping the point
where SLBP degradation started (Fig. 3A). We did not detect
significant phosphorylation of this substrate using lysates from
G1- or G1/S-phase cells. Note that there is an endogenous
protein phosphorylated by kinases in the extract (Fig. 3A)
which is present at similar levels in all lysates (also see Fig. 4B).
Since we have previously shown that in vivo the KRKL region
is required for both Thr61 phosphorylation and SLBP degra-
dation at S/G2, we tested the phosphorylation profile of
FIG. 2. A fragment of SLBP fused to GST is sufficient to mimic
S/G2 regulation of SLBP. (A) The SLBP fragment (amino acids 51 to
108) sufficient for S/G2 regulation is shown with the regions required
for late-S-phase degradation underlined. The Ser/Thr residues that
have been changed to alanine are shown by A below the wild-type
sequence. Mutations that have been introduced in different constructs
are indicated above the wild-type sequence. (B) HeLa cells stably
expressing the Myc-GST-SLBP fragment (mGST-SLBPF) with wild-
type TTP or TAP were synchronized by a double-thymidine block and
collected at S or G2 phase. The levels of mGST-SLBPF and endoge-
nous SLBP were determined by Western blot analysis using anti-Myc
and anti-SLBP (-Myc and -SLBP) antibodies. (C) In vitro kinase
assays with bacterially expressed GST-SLBPF (TTP, ATP, and TAP)
or GST alone were performed in the presence of [-32P]ATP, using
lysate from late-S-phase cells. The effect of roscovitine (Cdk1/Cdk2
inhibitor; 10 M) on phosphorylation was also determined. Samples
were analyzed by SDS-PAGE, and the phosphorylation level of each
substrate was determined by autoradiography.
TABLE 1. Effects of kinase inhibitors on SLBP degradation
Inhibitor Target(s)a Stable SLBPat G2
Roscovitine Cdk1, Cdk2 Yes
Wortmannin PI 3-kinase No
PD 98059 MEK 1 No
SB 202190 p38 MAPKs No




a MAPK, mitogen-activated protein kinase.
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KRKL/4A GST-SLBPF. In the absence of the KRKL se-
quence, we could not detect significant phosphorylation in
extracts from S and S/G2 cells (Fig. 3B, lanes 7 and 8), whereas
there was a small amount of phosphorylation detected in the
M/G1-phase lysate (Fig. 3B, lane 9). Addition of roscovitine to
the in vitro kinase assays abolished the phosphorylation of the
SLBP fragment and the residual phosphorylation seen in
M/G1-phase extracts on the KRKL/4A mutant, suggesting that
all the Thr61 phosphorylation, including the residual phosphor-
ylation of the KRKL/4A mutant in the M/G1-phase extract,
was mediated by a cyclin/Cdk (Fig. 3B).
We then performed similar experiments at 2-h intervals after
release from the thymidine block, repeating the same kinase
assays with different time points throughout S phase. We de-
tected phosphorylation peaking at late S phase (S/G2) on wild-
type GST-SLBPF and the ATP mutant but not the TAP mutant
(Fig. 4A), showing that the phosphorylation we detected oc-
curred on Thr61. Interestingly, although phosphorylation on
Thr61 significantly increased at S/G2, there was no significant
increase in the phosphorylation of H1, indicating that in this
experiment the cells had not reached the point in G2 where
cyclin B/Cdk1 activity rapidly increases. We analyzed incorpo-
ration of 32PO4 into all the extract proteins, and there was
similar total phosphorylation activity in the extract from each
time point (Fig. 4B). There were similar total kinase activities
in all the lysates, and the patterns of phosphorylated proteins
were similar in all the lysates. There was one band which was
phosphorylated in parallel with the GST-SLBPF substrate
which might be an endogenous substrate for the Thr61 kinase
(Fig. 4B, lanes 4 and 5).
Cyclin A/Cdk1 phosphorylates SLBP on Thr61. In order to
determine whether Cdk1 or Cdk2 was the major kinase re-
sponsible for the late-S-phase phosphorylation of Thr61, we
performed immunodepletion experiments using late-S-phase
lysates and Cdk1 or Cdk2 antibodies. In the case of Cdk2
depletion, although most of the Cdk2 was removed (Fig. 4C,
lane 1), there was no significant difference in Thr61 phosphor-
ylation. On the other hand, removal of even 40 to 50% of the
Cdk1 from the lysate (Fig. 4C, lane 2) significantly reduced the
phosphorylation on Thr61, suggesting that Cdk1 was the major
kinase that is responsible for the phosphorylation detected in
vitro. Mock depletion using the protein A beads alone had no
effect on the kinase activity (Fig. 4C, lanes 3 and 5). We further
reduced the amounts of Cdk1 in the extract by subjecting the
extract to sequential depletion with two treatments with the
anti-Cdk1 antibody. This treatment resulted in a further re-
duction of kinase activity using the GST-SLBPF substrate (Fig.
4C, lane 4) with no decrease in the amount of the Cdk2 pro-
tein.
We used antibodies against cyclin A and cyclin B to deplete
these proteins and their associated kinases (Fig. 4D). Deple-
tion of cyclin A resulted in a substantial reduction of kinase
activity using the GST-SLBPF substrate (Fig. 4D, lane 1), while
depletion of cyclin B (Fig. 4D, lane 2) had no effect. These
results suggest that cyclin A/Cdk1 might be the kinase respon-
sible for phosphorylating Thr61 of SLBP.
To determine the abilities of different cyclin/cdk’s to phos-
phorylate SLBP on Thr61, we immunoprecipitated cyclin A
and cyclin B complexes and Cdk2 or Cdk1 from late-S-phase
lysates and tested their ability to phosphorylate the wild-type
TTP, TAP, and KRKL/4A GST-SLBPF proteins using histone
H1 as a control substrate. With these substrates, we detected
phosphorylation only on GST-SLBPF containing TTP but not
on the TAP GST-SLBPF, consistent with the fact we detect
phosphorylation of SLBP only on Thr61. In order to determine
the cyclin partner, we immunoprecipitated cyclin A/cdk’s and
cyclin B/cdk’s and tested these kinase complexes for their abil-
ity to phosphorylate the GST-SLBPF proteins. Only cyclin
A/cdk, but not cyclin B/cdk, required the KRKL region to
phosphorylate Thr61 (Fig. 5A, lanes 1, 2, 6, and 7), indicating
that cyclin B/Cdk1 is not likely to be the kinase responsible for
Thr61 phosphorylation in vivo. Note that there is no phosphor-
ylation of KRKL/4A GST-SLBPF detected in the late-S-phase
lysates (Fig. 3B), although there is in the immunoprecipitates
(Fig. 5A, lane 7). There is a much higher kinase concentration
in the immunoprecipitates than in the lysates, and we presume
that at the higher concentration the cyclin B immunoprecipi-
tates can phosphorylate KRKL/4A GST-SLBPF.
We also used antibodies against Cdk2 or Cdk1 to immuno-
precipitate the cyclin/Cdk2 complexes and the cyclin/Cdk1
complexes from the same extracts and tested their ability to
phosphorylate GST-SLBP on Thr61. As a control, we deter-
mined the ability of the immunoprecipitates to phosphorylate
histone H1. The Cdk2 immunoprecipitates phosphorylated the
SLBP fragment only 1/3 as efficiently as they phosphorylated
histone H1 (Fig. 5B, lanes 1 and 3). All of this activity was
dependent on the KRKL sequence. In contrast, the Cdk1 im-
munoprecipitates phosphorylated the SLBP fragment better
FIG. 3. Lysates from late-S-phase cells phosphorylate GST-SLBPF
in a KRKL-dependent and roscovitine-sensitive manner. (A) In vitro
kinase assays were performed in the presence of [-32P]ATP, using
lysates from HeLa cells collected at indicated time points after the
double-thymidine block (top row). Equal amounts of protein from
total cell lysates were used in each lane. Samples were analyzed by
SDS-PAGE, and the phosphorylation level of the substrate was deter-
mined by autoradiography (top row). The levels of SLBP and cyclin A
were determined by Western blot analysis using anti-SLBP and anti-
cyclin A (CycA) antibodies (middle and bottom rows). The asterisk
indicates a closely migrating protein in the lysate whose phosphoryla-
tion level does not show significant change throughout the cell cycle.
(B) The effects of roscovitine (10 M) and the KRKL region on
phosphorylation of mGST-SLBPF were analyzed. The GST-SLBPF
protein with either the wild-type KRKL region or the 4A mutation was
used as a substrate (indicated below the panel).
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than they phosphorylated histone H1 (Fig. 5B, lanes 5 and 7).
The majority of this activity was dependent on the KRKL
sequence (Fig. 5B, lane 6). When we normalized the ability of
these Cdk immunoprecipitates to phosphorylate Thr61 to his-
tone H1, we found that the Cdk1 immunoprecipitates phos-
phorylated GST-SLBPF three to four times more efficiently
than the Cdk2 immunoprecipitates, further suggesting that a
cyclin/Cdk1 is the kinase that phosphorylates SLBP on Thr61
and triggers its degradation at late S phase.
The Cdk2 complexes present in the cell are cyclin A/Cdk2
and cyclin E/Cdk2. Since there is a constant high level of cyclin
A/Cdk2 activity during S phase and there is little Thr61 phos-
phorylation activity in the corresponding extracts (Fig. 4A), it
is unlikely that cyclin A/Cdk2 is responsible for the phosphor-
ylation of Thr61. The levels of cyclin E and cyclin E/Cdk2
activity are maximal in early S phase and low at late S phase
(9), suggesting that this kinase complex is not responsible for
the Thr61 kinase activity. The Cdk1 complexes that could be
present in the cell are cyclin A/Cdk1 and cyclin B/Cdk1, and
cyclin B/Cdk1 is the only known cyclin B/cdk complex.
We tested the abilities of recombinant cyclin A/Cdk2, cyclin
A/Cdk1, and cyclin B/Cdk1 in amounts that showed similar
histone H1 kinase activity (Fig. 5C, lanes 7 to 9) to phosphor-
ylate the GST-SLBPF fusion protein (Fig. 5C). Cyclin A/Cdk1
phosphorylated the GST-SLBPF proteins on Thr61 (Fig. 5C,
lanes 1 and 4), while cyclin A/Cdk2 had very little activity
toward these substrates (Fig. 5C, lanes 2 and 5). Cyclin B/Cdk1
also phosphorylated the GST-SLBPF substrate on Thr61 (Fig.
5C, lanes 3 and 6), although not as effectively as cyclin A/Cdk1.
We then tested whether the activities of the recombinant
kinases were dependent on the KRKL sequence, which is es-
sential for SLBP degradation (37). Recombinant cyclin
A/Cdk1 phosphorylated GST-SLBPF six times better than it
phosphorylated the GST-SLBPF KRKL mutant (Fig. 5D, lanes
1 and 2). In contrast, cyclin B/Cdk1 phosphorylated both GST-
SPBP fusion proteins equally well. Thus, all the data are con-
sistent with cyclin A/Cdk1 being the kinase responsible for
phosphorylating SLBP Thr61 at the end of S phase and trig-
gering SLBP degradation.
RNAi knockdown of Cdk1 results in stabilization of SLBP.
To further examine the role of Cdk1, we knocked down Cdk1
expression in synchronized HeLa cells using Cdk1-specific
FIG. 4. Phosphorylation in lysates from late-S-phase cells is on Thr61. (A) In vitro kinase assays with the indicated form of mGST-SLBPF (ATP,
TTP, or TAP) or histone H1 protein were performed in the presence of [-32P]ATP, using equal amounts of lysate from HeLa cells collected at
indicated time points after a double thymidine block (rows 4, 5, 6, and 7). Samples were analyzed by SDS-PAGE, and the phosphorylation level
of each substrate was determined by autoradiography (rows 4, 5, 6, and 7). Levels of cyclin A (Cyc A), cyclin B (Cyc B), and the SLBP protein
in the lysates were examined by Western blot analysis using corresponding antibodies (rows 1, 2, and 3). (B) An autoradiograph of the entire gel
is shown for the experiment in panel A, row 5. The asterisk indicates an endogenous protein that is phosphorylated in parallel with GST-SLBPF.
The positions of molecular mass markers are shown. (C) Late-S-phase HeLa cell lysates were immunodepleted with anti-Cdk1 (lanes 2), anti-Cdk2
(lane 1), or protein A beads (lanes 3 and 5) or double immunodepleted with anti-Cdk1 (lane 5). The levels of Cdk2 (top) and Cdk1 (middle) in
each lysate were determined by Western blot analysis with corresponding antibodies. The autoradiogram of the in vitro kinase assay using the
depleted extracts and GST-SLBPF as a substrate is shown at the bottom. (D) In vitro kinase assay using late-S-phase HeLa cell lysates
immunodepleted with anti-cyclin A (lane 1), anti-cyclin B (lane 2), or protein A beads (lane 3). The level of cyclin B (top) or cyclin A (middle)
remaining in each lysate was determined by Western blot (Wes.) analysis with corresponding antibodies. The autoradiogram of the in vitro kinase
assay (Kin.) using the depleted extracts and GST-SLBPF as a substrate is shown at the bottom. The phosphorylation level (Phos.) of each substrate
in panels C and D was quantified using a PhosphorImager and indicated as a percentage below the autoradiograph.
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RNA interference (RNAi) (Fig. 6). Using the strategy shown
in Fig. 6A, where siRNA treatment was combined with a dou-
ble-thymidine block, we have been able to partially knock
down Cdk1 while maintaining the ability to synchronize the
cells. Control cells were treated with the same siRNA protocol
using a control, C2 siRNA (C2) (31). The levels of the Cdk1
protein were reduced by approximately 50% by the RNAi
treatment (Fig. 6B, cf. lanes 1 to 3 with lanes 4 to 6). At 6 h
after release from the thymidine block, the cells were in late S
phase. There was less SLBP degradation at late S phase when
Cdk1 was knocked down compared to results for the control
cells (Fig. 6B, lanes 3 and 6). The amount of SLBP remaining
was normalized to a loading control, and the results of two
experiments are averaged in Fig. 6C. FACS analysis of these
cells showed that cells progressed through S phase and the cell
cycle distribution of the cells was comparable in the treated
and control cells (Fig. 6B, right).
Timing of SLBP degradation does not depend on Thr60
phosphorylation. Previously we showed that changing either
Thr60 or Thr61 to alanine stabilized SLBP at G2 (37). We
previously tested some of the possible changes of Thr60 and
Thr61 to acidic amino acids, but all of the changes we tested
stabilized SLBP (37). Specifically, we could not mimic the
phosphorylation on Thr61 by substitution with an acidic amino
acid, and the SFEEP mutant was also stable (37). We con-
structed additional mutants in an attempt to mimic the phos-
phorylation of Thr60 and created the SFEDP, SFDTP, and
SFETP mutants. We then selected populations of cells stably
expressing the mutant SLBP proteins at a level similar to that
for wild-type SLBP. The SFDTP mutant was stable at the end
of S phase, indicating that the aspartic acid at position 60 did
not mimic the phosphothreonine (Fig. 7A, bottom). In con-
trast, the SFETP mutant was regulated properly (Fig. 7A, top)
and was degraded in parallel with wild-type SLBP. This was the
only phosphorylation mutant that mimicked the wild-type pro-
tein (Fig. 7B). Treatment of the cells at 4 h after release with
the proteosome inhibitor MG132 stabilized endogenous SLBP
as well as the SFETP SLBP mutant protein (Fig. 7, lane 4).
This result demonstrated that the glutamic acid at position 60
was capable of mimicking this phosphothreonine and must be
able to target SLBP to the proteosome when Thr61 is also
phosphorylated. Since SFETP SLBP was expressed at normal
levels during S phase and then degraded, we conclude that
phosphorylation of Thr61 by cyclin A/Cdk1 is essential for
proper timing of the degradation of SLBP. In support of this,
it has been shown that cyclin A/Cdk1 is activated at the end of
S phase (21, 22). Thus, the mutagenesis data taken together
with our biochemical results implicate cyclin A/Cdk1 as the
kinase that phosphorylates Thr61 of SLBP, and this phosphor-
ylation triggers degradation of SLBP at the end of S phase.
CK2 phosphorylates Thr60, and phosphorylation is primed
by phosphorylation of Thr61. Analysis of the sequence around
the SFTTPE sequence in SLBP (http://cbs.dtu.dk/services
/NetPhosK) suggested that CK2 might phosphorylate T60. We
tested the involvement of CK2 as a possible Thr60 kinase by
using two different specific inhibitors of CK2, 4,5,6,7-tetra-
bromo-2-azabenzimidazole (TBB) and 2-dimethylamino-4,5,6,7-
tetrabromo-1H-benzimidazole (DMAT). Treatment of cells
with either TBB or DMAT at late S phase resulted in stabili-
zation of SLBP in G2, and the degree of stabilization was
dependent on the inhibitor concentration (Fig. 8A). Since CK2
phosphorylates serines or threonines which are often adjacent
to a negative charge (acidic amino acids or a phosphorylated
amino acid), we tested two synthetic peptide substrates that
contained amino acids 54 to 68 of SLBP, one of which had a
FIG. 5. The KRKL region is required for cyclin A/Cdk1 to phosphor-
ylate Thr61. (A) Cyclin A (Cyc A) (lanes 1 to 4) and cyclin B (Cyc B)
(lanes 6 to 9) immunoprecipitates (IP) from late-S-phase HeLa cell lysate
were used in in vitro kinase assays in the presence of [-32P]ATP. Phos-
phorylation on the GST-SLBPF proteins TTP (lanes 1, 5, 6, and 10),
KRKL/4A (lanes 2 and 7), TAP (lanes 4 and 9), and histone H1 (lanes 3
and 8) was detected by autoradiography. The phosphorylation level of
each substrate was quantified using a PhosphorImager. For each set of
reactions, the activity relative to that of histone H1 (set at 100) is given.
(B) Cdk2 (lanes 1 to 4) or Cdk1 (lanes 5 to 8) immunoprecipitates from
late-S-phase HeLa cell lysate were used in in vitro kinase assays in the
presence of [-32P]ATP. Phosphorylation of GST-SLBPF proteins TTP
(lanes 1, 5, and 9), KRKL/4A (lanes 2 and 6), and TAP (lanes 4 and 8),
and of histone H1 (lanes 3 and 7) was detected by autoradiography.
The phosphorylation level of each substrate was quantified by a
PhosphorImager and normalized against the level of histone H1 phos-
phorylation. In the mock lanes (panel A, lanes 5 and 10, and panel B, lane
9), immunoprecipitations were done with just protein A beads. (C) Re-
combinant cyclin A/Cdk1 (lanes 1, 4, and 7), cyclin A/Cdk2 (lanes 2, 5, and
8), or cyclin B/Cdk1 (lanes 3, 6, and 9) were incubated with GST-SLBPF
TTP (lanes 1 to 3) or ATP (lanes 4 to 6) or histone H1 (lanes 7 to 9) and
[-32P]ATP. The proteins were resolved by gel electrophoresis and the
phosphorylated proteins detected by autoradiography. The stained gel is
shown below the lane. The experiment shown corresponds to a single gel
and corresponding film image, with the assays with the different substrates
separated by several lanes. (D) Recombinant cyclin A/Cdk1 (lanes 1 to 3)
or cyclin B/Cdk1 (lanes 4 to 6) was incubated with GST-SLBPF TTP
(lanes 1 and 4), KRKL/4A (lanes 2 and 5), or TAP (lanes 3 and 6). The
proteins were resolved by gel electrophoresis and the phosphorylated
(Phos.) proteins detected by autoradiography and quantified with a
PhosphorImager. The activity was set at 100 for TTP with a particular
kinase. The stained gel is shown below the lane. The experiment shown
corresponds to a single gel and corresponding film image, with the assays
with the different kinases separated by several lanes.
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phosphothreonine at the equivalent of Thr61 and one which
had a threonine at this position. The unphosphorylated sub-
strate was not phosphorylated by CK2, but the phosphorylated
substrate was actively phosphorylated (Fig. 8B), suggesting
that phosphorylation of Thr61 primed the ability of CK2 to
phosphorylate Thr60. We subjected the phosphorylated pep-
tide to mass spectrometry analysis using a MALDI-time-of-
flight spectrometer, and about 40% of the phosphorylated pep-
tide was phosphorylated in a second site in 30 min (Fig. 8B,
right). We have confirmed that a significant amount of the
detected phosphorylation is on Thr60 by analysis of phos-
phoamino acids by thin-layer chromatography (data not
shown).
To demonstrate that cyclin A/Cdk1 could prime phosphory-
lation by CK2 on Thr60 in the context of the region of SLBP
that targets SLBP degradation, we carried out sequential phos-
phorylation reactions using our GST-SLBPF fusion proteins as
substrates. The first reaction was carried out in the presence of
unlabeled ATP in the presence or absence of recombinant
cyclin A/Cdk1, and then a second incubation was carried out
with radiolabeled ATP in the presence or absence of recom-
binant CK2. After 20 h of incubation at 30°C, cyclin A/Cdk1
was inactivated (Fig. 8C, lane 2), and incubation of the sub-
strate only with CK2 and radiolabeled ATP resulted in no
FIG. 6. Cdk1 knockdown inhibits late-S-phase SLBP degradation. (A) Outline of experimental setup for combining RNAi treatment with the synchroni-
zation procedure. (B) HeLa cells were transfected with Cdk1 siRNA (lanes 1 to 3) or a control siRNA (Cont.) (lanes 4 to 6), C2, followed by synchronization
with a double thymidine block. Cells were collected at the indicated time points after the release from the double thymidine block. The levels of Cdk1 and SLBP
were determined by Western blot analysis with corresponding antibodies. A cross-reacting band detected by the SLBP antiserum serves as a loading control.
FACS analysis of the 6-h time point from cells in panel B with percentage values for each cell cycle phase indicated is shown at the right. (C) The effects of the
RNAi treatment on SLBP levels, determined by densitometry of the Western blots from two independent experiments, were averaged.
FIG. 7. Changing Thr60 to Glu mimics phosphorylation of Thr60.
(A) The first threonine, T60, in the SFTTP motif was changed to either
glutamic acid (top) or aspartic acid (bottom) and stably expressed in HeLa
cells as His-tagged SLBP (HisSLBP). Cells were synchronized by a double
thymidine block and collected at the indicated hours after release. Levels of
exogenous mutated His-tagged SLBP and endogenous SLBP were deter-
mined by Western blot analysis using SLBP antibody. The cells in lane 4 (10
M) were treated with MG132 (proteosome inhibitor) at 4 h after release and
harvested at 10 h. (B) Summary of the effect of different mutations in the TTP
motif on G2 SLBP degradation. “Regulated” indicates they showed a G2
degradation profile similar to that of endogenous SLBP.
VOL. 28, 2008 PHOSPHORYLATION OF Thr61 TRIGGERS SLBP DEGRADATION 4475
FIG. 8. CK2 phosphorylates Thr60 of SLBP. (A) Western blot analysis of SLBP levels in HeLa cells which were treated 4 h after release from
a double thymidine block (at late S phase) and collected 4 h later at G2 with either DMSO (lanes 2 and 4) or different concentrations of two
different CK2 inhibitors, TBB (75 M [lane 3] or 50 M [lane 7]) or DMAT (20 M [lane 5] or 30 M [lane 6]). The loading control is a
cross-reacting band detected by the SLBP antisera. Lane 1 is a Western blot of cells 4 h after release prior to treatment. (B) The synthetic peptide
TTP (54RRPESFTTPEGPKPR68) or the same peptide with a phosphothreonine at Thr 61 (TphosTP) was incubated with recombinant CK2 and
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significant phosphorylation (Fig. 8C, lane 3). There was sub-
stantial phosphorylation of GST-SLBPF that was dependent on
the addition of CK2 and prior incubation with cyclin A/Cdk1
(Fig. 8C, lane 1). Phosphorylation by CK2 was dependent on
both the cyclin binding site in GST-SPBPF (Fig. 8C, lane 5) and
the presence of Thr61 in the substrate (Fig. 8C, lane 8).
We confirmed these results by analysis of the GST-SLBP
fragments by mass spectrometry. Using ESI (electrospray ion-
ization) to determine the molecular weight of the GST-SLBP
fragments, we showed that incubation with cyclin A/Cdk1 re-
sulted in addition of one phosphate to GST-SLBP and subse-
quent incubation with CK2 resulted in addition of a second
phosphate. The phosphorylation sites were confirmed as T61
and T60 by analysis by mass spectrometry on a MALDI TOF/
TOF spectrometer(data not shown).
We have identified the two kinases responsible for phosphor-
ylation of Thr60 and Thr61 that result in degradation of SLBP.
Cyclin A/Cdk1 phosphorylates Thr61 at the end of S phase,
and this phosphorylation is necessary for subsequent phosphor-
ylation by CK2 on Thr60. Thus, activation of cyclin A/Cdk1 is
responsible for the timing of SLBP degradation at the end of S
phase.
DISCUSSION
The molecular events that occur at late S phase or the S/G2
transition, at the completion of chromosome replication, are
poorly understood. Here we describe a cell cycle signaling
mechanism that corresponds to the end of S phase where
activation of cyclin A/Cdk1 results in an inhibition of histone
mRNA biosynthesis by triggering the degradation of the stem-
loop binding protein, the only known cell cycle-regulated pro-
tein in histone mRNA metabolism.
Thr60 and Thr61 phosphorylation mediates SLBP degrada-
tion at S/G2. We have previously shown that phosphorylation
of Thr60 and Thr61 is required for SLBP degradation at S/G2.
Along with those threonines, the adjacent Pro62 and a down-
stream putative cyclin binding site (KRKL) are required for
the Thr61 phosphorylation and SLBP degradation. Using sta-
ble expression of GST-SLBPF fragments containing only 57
amino acids, including both threonines and the KRKL region,
but with all other possible phosphoacceptor sites (Thr and Ser)
changed to alanine, we have shown that phosphorylation on
Thr60 and Thr61 within this fragment constitutes a sufficient
phosphorylation signal for SLBP degradation at the end of S
phase.
Cyclin A/Cdk1 triggers SLBP degradation at S/G2. The TP
motif and requirement of a downstream KRKL region which is
a putative cyclin binding site (RXL) suggested the involvement
of a cyclin/Cdk in SLBP degradation by phosphorylation of
Thr61. In support of this idea, we found that treatment of
HeLa cells with roscovitine, a Cdk1/Cdk2 inhibitor, at late S
phase inhibited the degradation of SLBP at S/G2. Further-
more, using our GST-SLBPF substrate for in vitro kinase as-
says, we showed that Thr61 kinase activity was detected only in
late-S-phase lysates and the activity was roscovitine sensitive,
supporting the idea that a cyclin/cdk is the Thr61 kinase.
Among the possible cyclin/cdk’s that could phosphorylate
GST-SLBPF based on the pattern of Thr kinase activity, we
conclude cyclin A/Cdk1 is likely the Thr61 kinase. This result
is supported by immunodepletion (Fig. 4) and immunoprecipi-
tation (Fig. 5A and B) experiments in vitro, studies with re-
combinant cyclin A/Cdk1, cyclin A/Cdk2, and cyclin B/Cdk1
(Fig. 5C and D), and Cdk1 knockdown experiments in vivo
(Fig. 6). Strikingly, cyclin A/Cdk1 but not cyclin A/Cdk2 phos-
phorylates T61 in vitro. Cyclin B/Cdk1 is also capable of phos-
phorylating T61 in vitro, but the activity is independent of the
cyclin binding motif, KRKL, that is required for degradation of
SLBP in vivo. These results suggest that the Cdk1 kinase can
recognize T61 while Cdk2 cannot.
Cyclin A/Cdk1 kinase activity is important at the end of S
phase. There is an increase in cyclin A/Cdk1 activity at the end
of S phase, and it increases prior to the activation of cyclin
B/Cdk1 (21, 22). This pattern of activity is distinct from that of
cyclin A/Cdk2, which is active throughout S phase and in-
creases only slightly during G2 (22, 24, 26). Although there is
high cyclin A/Cdk2 activity throughout S phase, both the in
vitro Thr61 kinase activity in cell lysates and the SLBP degra-
dation in vivo do not occur until the S/G2 border. Thus, the
Thr61 phosphorylation profile we detected correlates well with
cyclin A/Cdk1 activity which increases toward late S phase,
with a gradual increase toward the point where it peaks at G2
(21, 22).
In vitro, cyclin A/Cdk2 is capable of phosphorylating SLBP
on T61 at about 10% of the level observed with cyclin A/Cdk1.
Cyclin B/Cdk1 is also capable of phosphorylating SLBP on
T61, although this phosphorylation is not dependent on the
KRKL sequence, which is required for SLBP degradation in
vivo and for phosphorylation by either cyclin A kinase. In
S-phase extracts where cyclin A/Cdk2 activity is high, we did
not observe significant phosphorylation of T60. It is possible
that cyclin A/Cdk2 phosphorylates SLBP at a low rate and that
this accounts for the relatively short half-life (about 2 h) ob-
served for SLBP normally (34). It is also possible that cyclin
A/Cdk2 does not phosphorylate SLBP in vivo, possibly because
it is sequestered by other substrates. Based on the stability of
SLBP through mitosis when the KRKL sequence is mutated
[-32P]ATP, the peptides were bound to DEAE-paper, and the amount of the phosphorylated peptide was determined by liquid scintillation
counting. The results are the averages from two experiments. On the right is analysis of the peptide by MALDI-TOF after 30 min of incubation
with CK2. (C) The indicated GST-SLBPF substrates (above each lane) were incubated with unlabeled ATP and cyclin A/Cdk1 (lanes 1, 2, 4, 6, and
8) or buffer (lanes 3 and 7) overnight at 30°C. After the first incubation, CK2 (lanes 1, 3 to 5, 7, and 8) or buffer (lanes 2 and 6) was added together
with [-32P]ATP and incubation continued for 30 min. The proteins were resolved by gel electrophoresis and the phosphorylated GST-SLBPF
protein detected by autoradiography. GST-SLBPF was also incubated with unlabeled ATP and cyclin A/Cdk1 followed by CK2. GST-SLBPF was
analyzed by electrospray ionization mass spectrometry, and the deconvoluted spectra of GST-SLBPF are shown (right, top), as is GST-SLBPF after
incubation with cyclin A/Cdk1 (right, middle) and after incubation with cyclin A/Cdk1 followed by incubation with CK2 (right, bottom). The new
peaks in the middle and bottom panels correspond to addition of one and two phosphates, respectively. Rxn, reaction.
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(37), it is likely that cyclin B/Cdk1 does not phosphorylate
SLBP in vivo during mitosis, although it is more active than
cyclin A/Cdk2 in vitro. These differences most likely reflect the
differences (particularly the relatively high kinase and sub-
strate concentrations) between the in vivo and in vitro situa-
tions.
Several substrates for cyclin A/Cdk1 have been found, and
many of these are phosphorylated at the end of S phase or in
G2. One substrate is Orc1, which is phosphorylated in G2/M,
blocking its binding to chromatin, and this phosphorylation is
part of the mechanism that prevents rereplication of DNA
(14). Another substrate is the Flap endonuclease Fen1, which
is phosphorylated by cyclin A/Cdk1 in late S phase, resulting in
its dissociation from PCNA and likely playing a role in pre-
venting further DNA replication (12). A third target of cyclin
A/Cdk1 is the CCAAT displacement factor (CDP)/Cux tran-
scription factor. It is phosphorylated by cyclin A/Cdk1 in G2
phase, and this phosphorylation blocks DNA binding and
hence transcription activation activity (28). One target gene
which is downregulated as a result is DNA polymerase  (29).
The CDP/Cux transcription factor can also be phosphorylated
by cyclin A/Cdk2, but this phosphorylation is on a different site
and has no affect on the transcription activation activity (29).
Cyclin A/Cdk1 also participates in anaphase promoting com-
plex regulation, helping keep the anaphase promoting complex
inactive in late S phase and early G2 (21).
All of these substrates are involved in events that occur at
the end of S phase and in early G2, particularly in downregu-
lating the ability of cells to replicate DNA. The phosphoryla-
tion of SLBP by cyclin A/Cdk1 results in the subsequent deg-
radation of SLBP and effectively downregulates histone
mRNA biosynthesis. Thus, increasing cyclin A/Cdk1 activity at
the end of S phase results in downregulation of both DNA
replication and histone synthesis (Fig. 9).
A final known substrate of cyclin A/Cdk1 is CDC25B phos-
phatase, which is also targeted for degradation by phosphory-
lation by cyclin A/Cdk1 and is not phosphorylated by cyclin
B/Cdk1 (4). This is the only other known substrate which is
degraded as a result of phosphorylation by cyclin A/Cdk1. The
biological role of this phosphorylation of CDC25B is not clear,
but it may provide a mechanism for fine-tuning the activity of
cyclin A/Cdk1.
Phosphorylation of Thr61 likely triggers SLBP degradation
at the end of S phase. The results with the substitution of acidic
amino acids for Thr60 strongly suggest that the phosphoryla-
tion of Thr61 is the event that determines the timing of SLBP
degradation. Only one of the possible acidic amino acid sub-
stitutions, SFETP, resulted in an SLBP that was appropriately
regulated. Since in this mutant SLBP, Thr60 phosphorylation
was not regulated (since we replaced this amino acid with E),
we can conclude that Thr61 phosphorylation plays a role in
determining the timing of SLBP degradation at G2. The failure
of the SFEEP mutant to mimic the degradation signal is likely
due to a failure of the E3 ligase to recognize SFEEP. It is also
possible that the E3 ubiquitin ligase is cell cycle regulated and
is part of the timing mechanism. According to our model,
however, a critical component of the timing mechanism is an
increase in the cyclin A/Cdk1 activity at the end of S phase,
resulting in phosphorylation of SLBP at Thr61 and initiating
SLBP degradation.
Phosphorylation of Thr60 by CK2 requires phosphorylation
of Thr61 by cyclin A/Cdk1. We did not detect phosphorylation
of Thr60 in cell lysates in our experiments, either as a rosco-
vitine-resistant phosphorylation of the wild-type SLBP frag-
ment or as phosphorylation of the TAP mutant, raising the
possibility that phosphorylation of Thr60 requires prior phos-
phorylation of Thr61. Treatment of cells in late S phase with
CK2 inhibitors resulted in stabilization of SLBP at G2 (Fig.
8A), which led us to explore the possible role of CK2 in SLBP
phosphorylation. Sequential phosphorylations dependent on
an initial phosphorylation event are common (25), and the
CK2 consensus target sequence S/T()X() (19, 35), which
has a requirement for nearby negative charges, can be created
by priming phosphorylations by other kinases (19). SLBP also
has a conserved acidic amino acid at position 3 (Fig. 2A).
However, replacement of the glutamic acid (E63) with alanine
does not prevent degradation of SLBP (M. M. Koseoglu, un-
published data). Clearly some phosphorylation of Thr60 can
occur in the absence of Thr61 phosphorylation, since the
KRKL mutant SLBP is detectably phosphorylated in vivo on
Thr60 alone without Thr61 phosphorylation (37), although we
couldn’t quantify the level of this phosphorylation.
CK2 is a constitutively active Ser/Thr kinase which is ubiq-
uitously expressed throughout the cell cycle (15, 19). It is a
highly pleiotropic kinase which is involved in several cellular
events, including transcription, mRNA processing, translation,
and several aspects of cell cycle. CK2 activity is necessary for
both the G1/S and G2/M transition in yeast (10) and mamma-
lian cells (23, 33). CK2 activity is involved in Wee1 degradation
in G2, and this occurs at a similar time to that of SLBP deg-
radation (33). In both cases a cyclin/Cdk1 primes phosphory-
lation by CK2, resulting in production of a phosphodegron
which mediates degradation.
Our in vitro sequential phosphorylation analysis, along with
the in vivo effect of CK2 inhibition on SLBP stability, suggests
CK2 is the Thr60 kinase involved in SLBP degradation at the
end of S phase. Although all the in vitro data support a role for
CK2 in phosphorylating Thr60, we can’t totally rule out the
FIG. 9. Model for triggering SLBP degradation at S/G2. In contrast
to cyclin B/Cdk1 activity, which increases rapidly at G2/M, there is a
gradual increase in cyclin A/Cdk1 activity at the end of S phase that
reaches a sufficient level at the S/G2 border to phosphorylate Thr61 of
SLBP, and this primes subsequent phosphorylation of Thr60 by CK2 to
mark SLBP for degradation.
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possibility that there is a different kinase that does this in vivo
and that CK2 has an indirect effect on SLBP stability.
Conclusions. SLBP is the sole protein factor involved in
histone mRNA processing which is not present at cell cycle
phases other than S phase. Along with the regulation of his-
tone mRNA transcription and stability, cell cycle regulation of
SLBP is one of the mechanisms that limit histone mRNA
biosynthesis and thus histone production to S phase. Phosphor-
ylation of SLBP by cyclin A/Cdk1 and CK2 is one of the
mechanisms that effectively shuts down histone mRNA biosyn-
thesis at the end of S phase. When DNA replication is com-
pleted, histone mRNA is rapidly degraded, and this does not
require SLBP degradation (37). There are likely a number of
proteins degraded at the end of S phase, and it is possible that
cyclin A/Cdk1 may phosphorylate a number of other proteins
at this time to inhibit chromosome replication.
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